Category - Markets

Maxim Group downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “hold” from “buy” and eliminated its price target, saying it is not in agreement with the company in terms of its clinical plans. The stock closed at $1.14...

Roth Capital Partners initiated coverage of Arch Therapeutics (OTC:ARTH) with a ‘buy” rating and $3 price target. The stock closed at 66 cents on Feb. 13. Arch is developing an innovative product that produces a faster...

Leerink initiated coverage of Spark Therapeutics (NASDAQ:ONCE) with an “outperform” rating and $85 price target. The stock closed at $63.06 on Jan. 8. “While the stock has been a strong performer due to encouraging...

Maxim Group downgraded Galena Biopharma (NASDAQ:GALE) to “hold” from “buy” and removed its price target after the departure of Galena CEO, Dr. Mark Schwartz. The stock was quoted at $1.11 at midday Feb. 2. The Galena...

Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30. “Based on the clinical efficacy and safety profile of...

Stifel raised its price target for Momenta Pharmaceuticals (NASDAQ:MNTA) to $30 from $20 after a district court yesterday afternoon ruled that Teva Pharmaceutical’s Copaxone Q3W patents were invalid due to obviousness...

Stifel downgraded Ocera Therapeutics (NASDAQ:OCRX) to “hold” from “buy” and slashed its price target to $1 from $9 after the company reported top-line results from a Phase 2b study evaluating ornithine phenylacetate...

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on...

Maxim Group initiated coverage of Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and 12-month price target of $2. The stock was quoted at 42 cents at midday on Jan. 27. Analyst Jason Kolbert writes that...

Leerink downgraded Adocia (NXT PA:ADOC.FP) to “market perform” and slashed its price target to €15.00 from €82.00 after Eli Lilly terminated its collaboration for Adocia’s ultra-fast insulin product, BioChaperone Lispro...